The U.S. Food and Drug Administration approved Lembaz (adrabetadex) injection on Wednesday, marking the first therapy demonstrated to help patients with infantile-onset Niemann-Pick disease type C live longer. The approval addresses a critical gap for families managing this rare and severe genetic disorder.
Lembaz is indicated to reduce the risk of death in adult and pediatric patients who weigh at least 7 kilograms, or roughly 15 pounds, and whose neurological symptoms began before age 6. This specific subset of patients faces the most aggressive form of the disease, which causes progressive loss of movement, coordination, and swallowing ability.
Survival Benefits in Clinical Data
The approval is based on data from 36 patients treated with Lembaz across three clinical studies and an expanded access program. All participants had neurological manifestations of the disease prior to age 6. The FDA compared their outcomes against a matched external control group.
Patients receiving Lembaz showed a 55% reduction in the risk of death compared to the control group. The median survival time for the treated group was 8.5 years, significantly longer than the 4.9 years observed in the control group. This survival benefit remained consistent regardless of whether patients were also taking miglustat, a medication often used off-label for this condition.
“For families living with Niemann-Pick disease type C, today’s approval marks an important milestone,” said Acting FDA Commissioner Kyle Diamantas. “For the first time, there is a treatment shown to help adults and children with this serious disease live longer, and we are committed to continuing to support the development of therapies for the rare disease community.”
Administration and Safety Warnings
Lembaz is administered by a trained healthcare provider as an injection directly into the spinal canal, a procedure known as an intrathecal injection. Patients receive the dose every two weeks. The drug carries a boxed warning for hearing impairment, including the risk of permanent hearing loss.
The FDA recommends a comprehensive hearing evaluation before starting treatment and regularly throughout the course of therapy. Dose adjustments may be necessary based on the results of these evaluations. Other common side effects reported include problems with balance and coordination, fatigue, vomiting, back pain, headache, fever, diarrhea, nausea, and cough.
Before this approval, two other therapies were available for Niemann-Pick disease type C. However, neither had been shown to reduce the risk of death, and both carried age and weight restrictions that limited access for the youngest and most seriously affected patients. Lembaz is the first FDA-approved therapy to address mortality in this specific patient population.
Mandos, LLC, a subsidiary of Beren Therapeutics, PBC, received the approval for Lembaz. The drug had previously been granted Breakthrough Therapy designation by the FDA, a status intended to expedite the development and review of drugs that treat serious conditions and fill an unmet medical need.
Source: U.S. FDA

